Award details

Clostridium difficile endolysin therapeutic developments

Reference	BBS/E/F/00042529
Principal Investigator / Supervisor	Professor Arjan Narbad
Co-Investigators / Co-Supervisors	Professor Michael Gasson
Institution	Quadram Institute Bioscience
Department	Quadram Institute Bioscience Department
Funding type	Research
Value (£)	50,000
Status	Completed
Type	Institute Project
Start date	01/04/2009
End date	31/03/2010
Duration	12 months

Abstract

Clostridium difficile causes nosocomial disease with recently increased incidence and severity. Disease follows disruption of the normal GI tract microbiota, often following antibiotic treatment, emphasising the need to better target the pathogen without causing collateral damage to protective commensal species. We exploited the precise targeting of a bacteriophage endolysin (CD27L) derived from a C. difficile temperate bacteriophage to create a highly specific antimicrobial agent. CD27L has a very broad activity against C. difficile strains including ribotype027. GI tract commensal species and most other clostridia are insensitive. We propose to use recombinant lactic acid bacteria that express and release CD27L to overcome the challenges of GI tract delivery.

Summary

unavailable

Committee	Not funded via Committee
Research Topics	Microbiology, Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search